IN THE SPOTLIGHT

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

Tarlatamab Displays Overall Survival Benefit in Relapsed SCLC

Tarlatamab Displays Overall Survival Benefit in Relapsed SCLC

BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific

BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific

AstraZeneca's Drug Approved for Treating Limited-Stage Small Cell Lung Cancer in Europe

AstraZeneca's Drug Approved for Treating Limited-Stage Small Cell Lung Cancer in Europe

Small Cell Lung Cancer in 2024: Treatment Advances

Small Cell Lung Cancer in 2024: Treatment Advances

Continued Atezolizumab Shows Durable Benefit in Pretreated ES-SCLC

Continued Atezolizumab Shows Durable Benefit in Pretreated ES-SCLC

Triparna Sen: Lurbinectedin sensitizes PD-L1 blockade therapy in small-cell lung cancer

Triparna Sen: Lurbinectedin sensitizes PD-L1 blockade therapy in small-cell lung cancer

Top advances of the year: Small cell lung cancer

Top advances of the year: Small cell lung cancer

Basic science and translational implications of current knowledge on neuroendocrine tumors

Basic science and translational implications of current knowledge on neuroendocrine tumors